Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease.
Aged
Aged, 80 and over
Biomarkers
/ analysis
Disease Progression
Female
Humans
Idiopathic Pulmonary Fibrosis
/ diagnosis
Lung
/ diagnostic imaging
Lung Diseases, Interstitial
/ diagnosis
Male
Middle Aged
Predictive Value of Tests
Prognosis
Prospective Studies
Retrospective Studies
Tomography, X-Ray Computed
WAP Four-Disulfide Core Domain Protein 2
/ analysis
Biomarker
Honeycombing
Human epididymis protein 4
Prognosis
Progressive fibrosing interstitial lung disease
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
13
06
2020
revised:
31
07
2020
accepted:
03
08
2020
pubmed:
14
9
2020
medline:
29
6
2021
entrez:
13
9
2020
Statut:
ppublish
Résumé
The clinical course and prognosis of progressive fibrosing interstitial lung diseases (PF-ILDs) vary between individuals. Notably, predictive serum biomarkers for disease management are needed. Serum human epididymis protein 4 (HE4) is reportedly elevated in patients with idiopathic pulmonary fibrosis (IPF); however, its clinical utility remains unknown. We evaluated the potential of serum HE4 as a biomarker for patients with PF-ILD. Serum HE4 was measured in a retrospective study consisting of 34 patients with PF-ILD and 40 healthy volunteers. The relationship between serum HE4 levels and clinical parameters or prognosis was investigated. To validate the significance of results obtained, a prospective observational study was performed in 37 patients presenting PF-ILD and 40 control patients without PF-ILD. Serum HE4 levels were higher in patients with PF-ILD than in healthy volunteers (P < 0.01). Moreover, serum HE4 levels correlated with the extent of honeycombing on chest high-resolution computed tomography (r = 0.41, P = 0.015). In multivariate analysis using the Cox proportional hazard model, higher HE4 levels (>238 pmol/L) were associated with an elevated mortality risk; hazard ratio (HR) 7.27, 95% CI 1.56-34.0, P = 0.01 in the derivation cohort; HR 44.3, 95% CI 4.19-468, P < 0.01 in validation cohort. Serum HE4 levels may serve as a new diagnostic and prognostic biomarker for patients with PF-ILD.
Sections du résumé
BACKGROUND
BACKGROUND
The clinical course and prognosis of progressive fibrosing interstitial lung diseases (PF-ILDs) vary between individuals. Notably, predictive serum biomarkers for disease management are needed. Serum human epididymis protein 4 (HE4) is reportedly elevated in patients with idiopathic pulmonary fibrosis (IPF); however, its clinical utility remains unknown. We evaluated the potential of serum HE4 as a biomarker for patients with PF-ILD.
METHODS
METHODS
Serum HE4 was measured in a retrospective study consisting of 34 patients with PF-ILD and 40 healthy volunteers. The relationship between serum HE4 levels and clinical parameters or prognosis was investigated. To validate the significance of results obtained, a prospective observational study was performed in 37 patients presenting PF-ILD and 40 control patients without PF-ILD.
RESULTS
RESULTS
Serum HE4 levels were higher in patients with PF-ILD than in healthy volunteers (P < 0.01). Moreover, serum HE4 levels correlated with the extent of honeycombing on chest high-resolution computed tomography (r = 0.41, P = 0.015). In multivariate analysis using the Cox proportional hazard model, higher HE4 levels (>238 pmol/L) were associated with an elevated mortality risk; hazard ratio (HR) 7.27, 95% CI 1.56-34.0, P = 0.01 in the derivation cohort; HR 44.3, 95% CI 4.19-468, P < 0.01 in validation cohort.
CONCLUSIONS
CONCLUSIONS
Serum HE4 levels may serve as a new diagnostic and prognostic biomarker for patients with PF-ILD.
Identifiants
pubmed: 32919933
pii: S2212-5345(20)30118-0
doi: 10.1016/j.resinv.2020.08.002
pii:
doi:
Substances chimiques
Biomarkers
0
WAP Four-Disulfide Core Domain Protein 2
0
WFDC2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-98Informations de copyright
Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest Abbott Japan LLC covered the costs for serum HE4 measurement. K.M has an employment relationship with Abbott Japan, LLC.